Acutaas Chemicals Ltd
NSE:ACUTAAS
Acutaas Chemicals Ltd
NSE:ACUTAAS
Price:
2 527.3
INR
3.78%
Market Closed
Market Cap:
₹206.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Acutaas Chemicals Ltd
NSE:ACUTAAS
|
IN |
|
Fubotv Inc
NYSE:FUBO
|
US |
|
JMD Ventures Ltd
BSE:511092
|
IN |
|
Xinyi Glass Holdings Ltd
HKEX:868
|
HK |
|
E
|
Elicera Therapeutics AB
STO:ELIC
|
SE |
|
Journey Medical Corp
NASDAQ:DERM
|
US |
|
Asia Financial Holdings Ltd
HKEX:662
|
HK |
|
R
|
Reserve Petroleum Co
OTC:RSRV
|
US |
|
K
|
Kakatiya Textiles Ltd
BSE:521054
|
IN |
|
D
|
DL Holdings Group Ltd
HKEX:1709
|
HK |
|
S
|
SBFC Finance Ltd
BSE:543959
|
IN |
|
Neinor Homes SA
MAD:HOME
|
ES |
|
M
|
MREIT Inc
XPHS:MREIT
|
PH |
Multiples-Based Value
The Multiples-Based Value of one
ACUTAAS
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 2 527.3 INR,
Acutaas Chemicals Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ACUTAAS Multiples-Based Value
LOCKED
Multiples Across Competitors
ACUTAAS Competitors Multiples
Acutaas Chemicals Ltd Competitors
Acutaas Chemicals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Acutaas Chemicals Ltd
NSE:ACUTAAS
|
206.9B INR | 17 | 71.9 | 54.5 | 59.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
